Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Call Transcript

Dave Lennon: Great. Thank you. Well, thanks, everyone, for joining the call this morning. Thanks to Scott, Loretta and Audrey for supporting this. And I wanted to remind everyone that we really had great progress over the course of this year, particularly around our clinical study and development programs. We have now fully enrolled our PRECISION1 trial and look forward to our two-thirds interim analysis in quarter three of this year, which will be a major milestone for us and determining where we go next with TSC1 and TSC2 mutant cancers, which are really large opportunity for us to expand the nab-sirolimus portfolio. We’re also really excited about the progress we’ve seen in EEC and NETs enrollment and look forward to early updates on those programs later this year.

And then finally, we expect to return to growth for FYARRO in Q2 of 2024 and look forward to sharing updates on that as we progress our commercial business. Otherwise, thank you for joining the call today, and we look forward to further updates as we go through the year. Thanks, everyone. Bye now.

Operator: Thank you for your participation in today’s conference. This concludes the program. You may now disconnect.